Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 22, 2009

Genetic Tech to Distribute Rosetta’s Cancer Tests in Australia, New Zealand, and Singapore

  • Australia-based Genetic Technologies obtained exclusive distribution rights to Rosetta Genomics’ miRNA-based cancer tests—miRview™ mets, miRview™ squamous, and miRview™ meso—in Australia, New Zealand, and Singapore.

    miRview mets is designed to accurately identify the primary tumor site in patients presenting with metastatic cancer and those with cancer of unknown primary. miRview squamous differentiates squamous from nonsquamous non-small-cell lung cancer. miRview meso uses miRNA specificity as biomarkers to differentiate mesothelioma from other lung carcinomas. 

    Rosetta’s deal with Genetic Technologies follows a September agreement with AXA Diagnostics for distribution of the same three tests in Italy.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »